Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025
Soleno Therapeutics (Nasdaq: SLNO) released preliminary Q2 2025 financial results, highlighting strong performance of its recently approved drug VYKAT� XR. The company projects Q2 net revenue between $31.0-$33.0 million from VYKAT� XR sales.
Key metrics include $293.8 million in cash and equivalents, 646 patient start forms from 295 unique prescribers since VYKAT� XR's March 26 approval, and $50.0 million in outstanding debt. The company notes these results are preliminary and subject to final review.
Soleno Therapeutics (Nasdaq: SLNO) ha pubblicato i risultati finanziari preliminari del secondo trimestre 2025, evidenziando la forte performance del suo farmaco recentemente approvato VYKAT� XR. L'azienda prevede un fatturato netto per il secondo trimestre compreso tra 31,0 e 33,0 milioni di dollari derivante dalle vendite di VYKAT� XR.
Le metriche principali includono 293,8 milioni di dollari in liquidità e equivalenti, 646 moduli di avvio paziente da parte di 295 prescrittori unici dalla data di approvazione di VYKAT� XR del 26 marzo, e 50,0 milioni di dollari di debito residuo. L'azienda precisa che questi risultati sono preliminari e soggetti a revisione finale.
Soleno Therapeutics (Nasdaq: SLNO) publicó resultados financieros preliminares del segundo trimestre de 2025, destacando el sólido desempeño de su medicamento recientemente aprobado VYKATâ„� XR. La compañÃa proyecta ingresos netos para el segundo trimestre entre 31,0 y 33,0 millones de dólares por ventas de VYKATâ„� XR.
Las métricas clave incluyen 293,8 millones de dólares en efectivo y equivalentes, 646 formularios de inicio de pacientes de 295 prescriptores únicos desde la aprobación de VYKAT� XR el 26 de marzo, y 50,0 millones de dólares en deuda pendiente. La empresa señala que estos resultados son preliminares y están sujetos a revisión final.
ì†”ë ˆë…� í…Œë¼í“¨í‹±ìŠ� (나스ë‹�: SLNO)ëŠ� 2025ë…� 2분기 예비 재무 ê²°ê³¼ë¥� 발표하며 최근 승ì¸ë� 약물 VYKATâ„� XRì� ê°•ë ¥í•� 실ì ì� 강조했습니다. 회사ëŠ� VYKATâ„� XR íŒë§¤ë¡� 2분기 ìˆœë§¤ì¶œì´ 3,100ë§Œ~3,300ë§� 달러ì—� ì´ë¥¼ 것으ë¡� 예ìƒí•©ë‹ˆë‹�.
주요 지표로ëŠ� 현금 ë°� 현금ì„� ìžì‚° 2ì–� 9,380ë§� 달러, 3ì›� 26ì� VYKATâ„� XR ìŠ¹ì¸ ì´í›„ 295ëª…ì˜ ê³ ìœ ì²˜ë°©ìž�로부í„� 646ê±´ì˜ í™˜ìž ì‹œìž‘ ì–‘ì‹, 그리ê³� 5,000ë§� 달러ì� 미지ê¸� 부채가 í¬í•¨ë©ë‹ˆë‹�. 회사ëŠ� ì� 결과가 예비 수치ì´ë©° 최종 ê²€í† ë¥¼ ê±°ì¹ ì˜ˆì •ìž„ì„ ë°í˜”습니ë‹�.
Soleno Therapeutics (Nasdaq : SLNO) a publié les résultats financiers préliminaires du deuxième trimestre 2025, mettant en avant la solide performance de son médicament récemment approuvé VYKAT� XR. La société prévoit un chiffre d'affaires net pour le deuxième trimestre compris entre 31,0 et 33,0 millions de dollars provenant des ventes de VYKAT� XR.
Les indicateurs clés comprennent 293,8 millions de dollars en liquidités et équivalents, 646 formulaires de début de traitement de 295 prescripteurs uniques depuis l'approbation de VYKAT� XR le 26 mars, ainsi qu'une dette en cours de 50,0 millions de dollars. La société précise que ces résultats sont préliminaires et soumis à une révision finale.
Soleno Therapeutics (Nasdaq: SLNO) veröffentlichte vorläufige Finanzergebnisse für das zweite Quartal 2025 und hob die starke Leistung seines kürzlich zugelassenen Medikaments VYKAT� XR hervor. Das Unternehmen prognostiziert einen Nettoumsatz im zweiten Quartal zwischen 31,0 und 33,0 Millionen US-Dollar aus dem Verkauf von VYKAT� XR.
Wichtige Kennzahlen umfassen 293,8 Millionen US-Dollar an liquiden Mitteln und Äquivalenten, 646 Patientenstartformulare von 295 einzigartigen Verschreibern seit der Zulassung von VYKAT� XR am 26. März sowie 50,0 Millionen US-Dollar ausstehende Schulden. Das Unternehmen weist darauf hin, dass diese Ergebnisse vorläufig sind und einer abschließenden Prüfung unterliegen.
- Strong initial VYKAT� XR sales projected at $31-33 million in first full quarter
- Robust cash position of $293.8 million provides significant operational runway
- Significant prescriber adoption with 295 unique prescribers in first 3 months
- Strong patient uptake with 646 start forms since March launch
- $50.0 million debt obligation remains outstanding
- Financial results are preliminary and subject to potential changes
Insights
Soleno's newly approved VYKAT XR generates strong initial revenue of $31-33M with solid prescriber adoption and healthy cash position.
Soleno Therapeutics has released preliminary Q2 2025 financial results that reveal impressive early commercial traction for VYKAT XR, which was just approved on March 26, 2025. The drug generated between
The company's strong cash position of approximately
VYKAT XR's market penetration metrics are particularly encouraging, with 646 patient start forms submitted by 295 unique prescribers in just over three months since approval. This equates to an average of 2.2 patients per prescriber, suggesting both broad physician adoption and early practitioner comfort with prescribing the medication multiple times.
The company's
These preliminary results indicate Soleno is executing well on its commercialization strategy for VYKAT XR in the rare disease space, with strong initial prescriber adoption suggesting significant market demand for this novel therapeutic option.
REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today certain preliminary unaudited financial and operational results for the three months ended June 30, 2025:
- Soleno expects its net revenue from the sales of VYKATTM XR, for the three months ended June 30, 2025 to be between
$31.0 million and$33.0 million . Soleno has determined net revenue for VYKATTM XR with specific assumptions for Medicare/Medicaid rebates, chargebacks, copay assistance, returns reserve and prompt pay discounts. - Soleno had approximately
$293.8 million in cash, cash equivalents and marketable securities as of June 30, 2025. - Soleno received approximately 646 patient start forms from approximately 295 unique prescribers between March 26, 2025, the date of approval of its lead product candidate, VYKAT� XR, and June 30, 2025.
- Soleno continued to have approximately
$50.0 million of debt outstanding under its loan and security agreement with Oxford Financing LLC and its affiliates as of June 30, 2025.
Soleno has not yet completed its financial close and review processes for the three months ended June 30, 2025. The review of Soleno’s financial statements for the three months ended June 30, 2025 is ongoing and could result in changes to the financial results estimated above. The estimates of Soleno’s net revenue, cash, cash equivalents and marketable securities, patient start forms, and unique prescribers, as of June 30, 2025 are preliminary, have not been audited, do not present all information necessary for an understanding of Soleno’s financial condition as of June 30, 2025, and are subject to change upon completion of Soleno’s financial statement closing procedures. The preliminary financial data included in the above has been prepared by, and is the responsibility of, Soleno’s management. Soleno’s independent registered public accounting firm has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s first commercial product, VYKATTM XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements about Soleno’s expectations for its preliminary financial and operating results for the three months ended June 30, 2025, and all other statements that are not statements of historical facts. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed public offering, as well as risks and uncertainties inherent in Soleno’s business, including those described in Soleno’s Annual Report on Form 10-K for the year ended December 31, 2024, Soleno’s Quarterly Report on Form 10-Q for the three month period ended March 31, 2025, prior press releases and in other filings and reports filed with the SEC. The events and circumstances reflected in Soleno’s forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, Soleno does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578Ìý
Media Contact:
